5 assets in Attention Deficit-Hyperactivity Disorder

Therapeutic assets addressing Attention Deficit-Hyperactivity Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Methylphenidate Attention Deficit-Hyperactivity Disorder	Hugo W. Moser Research Institute at Kennedy Krieger, Inc.	P4	BBB (76)
Dextromethorphan Attention Deficit-Hyperactivity Disorder	Prof. Dr. Frank Behrens	P2	CCC (53)
Sertraline Attention Deficit-Hyperactivity Disorder	Holland Bloorview Kids Rehabilitation Hospital	P2	CCC (53)
Risperidone Attention Deficit-Hyperactivity Disorder	Spanish Foundation for Neurometrics Development	P4	NR ()